阿帕替尼联合紫杉醇治疗晚期食管癌的临床疗效及对血管内皮生长因子水平的影响

The clinical efficacy of apatinib combined with paclitaxel in the treatment of advanced esophageal cancer and its influence on the level of vascular endothelial growth factor

目的探索阿帕替尼联合紫杉醇治疗晚期食管癌的临床疗效及对血管内皮生长因子水平的影响。方法收集分析2018年1月-2019年10月于联勤保障部队第九八八医院治疗的94例晚期食管癌患者的临床资料,依据不同的治疗方案将患者分成两组,观察组为阿帕替尼联合紫杉醇治疗的晚期食管癌患者,对照组为单纯应用紫杉醇治疗的晚期食管癌患者,21 d为一周期,治疗4周期后评估疗效、不良反应及血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平。结果两组相比,治疗4周期后,观察组病情控制率为79.5%,对照组食管恶性肿瘤患者病情控制率为59.1%,差异具有统计学意义(P<0.05);治疗后两组患者VEGF水平均有明显降低,且观察组低于对照组,差异有统计学意义(P<0.05);患者不良反应在对症处理后均有所缓解,不影响临床治疗,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿帕替尼联合紫杉醇在晚期、一线治疗失败或术后复发的食管癌患者中的疗效优于单纯的化学治疗。

Objective To explore the clinical efficacy of apatinib combined with paclitaxel in the treatment of advanced esophageal cancer and its influence on the level of vascular endothelial growth factor.Methods The clinical data of 88 patients with advanced esophageal cancer treated in our hospital from January 2018 to October 2019 were collected and analyzed.According to different treatment schemes,all patients were divided into two groups.The observation group was treated by apatinib and paclitaxel,and the control group was treated with paclitaxel alone.After 4 cycles of treatment,the efficacy,adverse reactions and serum VEGF levels were evaluated.Results After 4 cycles of treatment,the disease control rate of the experimental group was 79.5%,and that of the control group was 59.1%.The difference between the two groups was statistically significant;after treatment,the level of vascular endothelial growth factor between two groups was significantly lower,and that of the observation group was lower than that ofthe control group,the difference was statistically significant(P<0.05).The adverse reactions were all relievedafter symptomatic treatment.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of apatinib combined with paclitaxel is better than that of chemotherapy alone in patients with advanced esophageal cancer,or patientsbeing failure at first-line treatment or having postoperative recurrence.